SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Michael Murray, Adam Hraiki, Mary Bebawy, Curtis Pazderka, Tristan Rawling, Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs, Pharmacology & Therapeutics, 2015, 150, 109

    CrossRef

  2. 2
    Hui Jun Lim, Philip Crowe, Jia-Lin Yang, Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer, Journal of Cancer Research and Clinical Oncology, 2015, 141, 4, 671

    CrossRef

  3. 3
    Wenhu Zhan, Sendong Lin, Jing Chen, Xiaowu Dong, Jianbo Chu, Wenting Du, Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors, Chemical Biology & Drug Design, 2015, 85, 6
  4. 4
    Silvia Ortolani, Chiara Ciccarese, Sara Cingarlini, Giampaolo Tortora, Francesco Massari, Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives, Future Oncology, 2015, 11, 12, 1809

    CrossRef

  5. 5
    William D. Figg, Manish Monga, Donna Headlee, Avni Shah, Cindy H. Chau, Cody Peer, Richard Messman, Yusri A. Elsayed, Anthony J. Murgo, Giovanni Melillo, Qin C. Ryan, Mikhail Kalnitskiy, Adrian M. Senderowicz, Melinda Hollingshead, Susan G. Arbuck, Edward A. Sausville, A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms, Cancer Chemotherapy and Pharmacology, 2014, 74, 5, 955

    CrossRef

  6. 6
    Susanne Koeppen, Im Fokus: die Blockade mit Kinaseinhibitoren, Im Focus Onkologie, 2014, 17, 5, 48

    CrossRef

  7. 7
    Eva Juengel, Jasmina Makarević, Michael Reiter, Jens Mani, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta, Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism, Neoplasia, 2014, 16, 4, 291

    CrossRef

  8. 8
    Gordian L. Schmid, Franziska Kässner, Holm H. Uhlig, Antje Körner, Jürgen Kratzsch, Norman Händel, Fred-P. Zepp, Frank Kowalzik, Andreas Laner, Sven Starke, Franziska K. Wilhelm, Susanne Schuster, Adrian Viehweger, Wolfgang Hirsch, Wieland Kiess, Antje Garten, Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies, Pediatric Research, 2014, 75, 4, 527

    CrossRef

  9. 9
    Daniel Cho, Novel Targeting of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin in Renal Cell Carcinoma, The Cancer Journal, 2013, 19, 4, 311

    CrossRef

  10. 10
    Alessandro Conti, Matteo Santoni, Consuelo Amantini, Luciano Burattini, Rossana Berardi, Giorgio Santoni, Stefano Cascinu, Giovanni Muzzonigro, Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma, BioMed Research International, 2013, 2013, 1

    CrossRef

  11. 11
    Mikhail V Blagosklonny, Selective anti-cancer agents as anti-aging drugs, Cancer Biology & Therapy, 2013, 14, 12, 1092

    CrossRef

  12. 12
    Eva M. Palsson-McDermott, Luke A. J. O'Neill, The Warburg effect then and now: From cancer to inflammatory diseases, BioEssays, 2013, 35, 11
  13. 13
    Simona Wagner, Janet Dancey, Targeted Therapies in Oncology, Second Edition, 2013,

    CrossRef